ICH Q3A (R2) Impurities in new drug substances Description, This document provides guidance on the content and qualification of impurities. Center for Biologics Evaluation and Research (CBER). June ICH . This is the second revision of the Q3A guidance, which was published in and. This guideline deals with impurities (organic, inorganic and residual solvents) in new active Q3A
|Published (Last):||1 December 2012|
|PDF File Size:||11.59 Mb|
|ePub File Size:||6.26 Mb|
|Price:||Free* [*Free Regsitration Required]|
Ideally, guiidelines impurities should be eliminated by modification of the formulation, synthetic route, starting materials, reactants, or through additional purification. Click here to submit your manuscript Therefore, the k m factor for a human is calculated by dividing 60 by 1.
As per the ICH Q3A R2 1 guideline, impurities in the drug substance below the qualification threshold levels do not need to be qualified unless the impurity is expected to be unusually toxic or potent Table 1. As the program develops, adherence to ICH impurity guidelines is required.
Drug substance and drug product impurities, now what? Impurities in drug substances may include starting materials, intermediates, degradation products, etc. The identification threshold is the level at which an impurity must be structurally identified. Toxicology studies to establish safety should compare the new drug substance or drug product containing a representative amount of the new impurity with previously qualified test article or using the isolated impurity only.
Drug substance and drug product impurities, now what?
The toxicology studies needed to qualify a drug product impurity follow those cited above for impurities in drug substances. Impurities in the drug substance primarily originate during the synthetic process using raw materials, intermediates, and by-products present in the reaction mixture at much lower purity requirements than for the drug substance. This approach could potentially save precious time at the latter stages of drug development. When an impurity in the drug substance reaches the qualification threshold level, it is the responsibility of the sponsor to establish the safety of the impurity.
If the daily intake of an impurity is above the acceptable intake levels, the impurity should be identified and a stepwise approach can be taken for qualification.
ICH Q3A (R2) Impurities in new drug substances | European Medicines Agency
Human Equivalent Dose; Km: These early toxicology studies will then increase the chances that any particular impurity will be present in the drug substance at levels considered qualified, especially when the drug substance impurity is present at multiples higher than clinical exposure. Insights regarding acceptable amounts of residual solvents and the calculation of permitted daily exposures will be the subject of another review. Genotoxic impurities and degradation products pose an additional risk and should be controlled in accordance with the M7 R1 4 guidances, unless qualified for safety.
However, for the toxicologist the issue for any impurity that exceeds qualification thresholds is whether sufficient safety information exists, either in completed nonclinical or clinical studies or in the literature, to support continued development or whether the impurity needs to be guideilnes through the conduct of additional safety studies.
Is the impurity toxic? The focus of the M7 R1 2 guideline is on DNA reactive substances that have a potential to directly cause DNA damage when present at low levels guidelinnes to mutations and therefore, potentially causing cancer.
If neither option is feasible, empirical toxicology testing will have to be performed to qualify the impurity. This involves converting the no observed adverse effect level NOAEL doses in the most relevant animal species to the human equivalent doses HED based on body surface area, recognizing that larger icb typically have lower metabilic rates.
February 27, Correspondence: Qualification of drug substance and drug product impurities are broadly dependent on the maximum theoretical clinical dose, whereas potential mutagenic impurities must be controlled to levels less than the threshold of guideliens concern based on lifetime exposure. The reporting threshold is the level at which an impurity must be reported with the analytical procedures indicated.
This dose-by-factor strategy is based on minimum risk of toxicity rather than minimum guuidelines activity. Sponsors are encouraged to master the guidance documents discussed in this mini-review and consult a qualified expert with any questions or for assistance in assessing specific impurity issues.
Table 1 presents the drug substance impurity thresholds described in ICH Q3A R2 1 which trigger reporting, identification, and qualification requirements.
Impurities in New Drug Substances : ICH
The correction factor k m is estimated by dividing the average body weight kg for the species by that species body surface area m 2. Impurities that are also significant metabolites present guidelunes animal or human studies are generally considered qualified.
Potential issues with impurities are one reason why toxicology studies completed early in the development program are often completed with drug substance of lower purity. What do we do now? Drug substance and drug product impurities are a current hot button issue with regulatory authorities. The most accurate predictions occur for renally excreted compounds with low hepatic metabolism and a low volume of distribution.
Given the apparent increased scrutiny regarding impurities, toxicology programs for molecules early in development should consider using a well-characterized drug substance of lower purity. Drug product impurities are defined as, and limited to, degradation products of the drug substance, and reaction products of the drug substance with excipients or the container-closure system.
February 21, Published: This practice increases the chances that any potential impurity will be present in the drug substance and thus considered qualified icch that study when the drug substance impurity is present at multiples higher than the clinical exposure. To limit a possible human cancer risk associated with the exposure to potentially mutagenic impurities, the Ames assay is used to assess the mutagenic potential.
The decision tree for the identification guideoines qualification of drug substance impurities see Attachment 3 in the ICH Q3A R2 guideline should be closely followed and thoroughly discussed with the regulatory authority to resolve drug substance impurity issues.